Introduction
Neuroligin 1 (NLGN1) is a synaptic protein expressed on endothelial cells (ECs) that modulates angiogenesis and EC adhesion in cooperation with the laminin-binding integrin alpha6 beta1 [1] . Nonetheless, another Neuroligin isoform, Neuroligin 2 (NLGN2), is also highly produced by ECs, but its vascular activities do not overlap with those of NLGN1 [1] . Interestingly, outside of the CNS, NLGN2 is involved in insulin release from pancreatic cells [2] .
Angiopoietin 2 (Ang2) is a vascular mediator with diverse activities, ranging from vessel sprouting to vascular permeability and inflammation [3] that is stored in secretory organelles of ECs called Weibel-Palade bodies (WPB) [4] along with von Willebrand factor (vWF) and a number of other vascular regulators. Vascular endothelial growth factor (VEGF) is an agonist of Ang2 release from ECs with a prominent role in tumor angiogenesis and vascular remodeling [3] . Here, we report the finding that endothelial NLGN2 modulates the VEGF-induced Ang2 and vWF release from ECs in vitro and in vivo, in cooperation with a neuronal Guanine Exchange Factor (GEF) for the small GTPase CDC42. Moreover, NLGN2 null mice display an altered vascular pattern and reduced pericyte coverage of vessels both in the neonatal retina and in subcutaneous tumors. These phenotypes are compatible with the lack of an agonistic activity of Ang2 towards its receptor Tie2.
Materials and Methods

Animals : Mice lacking NLGN2 (Nlgn2 tm1
Bros/J -Jackson Laboratory), previously described [5] , were maintained on a mixed C57BL/6 x 129 background (designated B6; 129) in the animal facility of the Institute (IRCC) under standard housing conditions. Mice were sacrificed at P5 and retinas were isolated for analysis. PCR amplification was used for the genotype characterization using the forward common primer (5'GTGAGCTGAATCTTATGGTTAGATGGG3'), the wild-type reverse primer: (5'CCCATCAGTGTACCATTCCCTAAA3'), and the mutant reverse primer (5'GAGCGCGCGCGGCGGAGTTGTTGAC3'). All animal experiments were performed in compliance with guidelines governing the care of laboratory mice of the University of Torino Committee on Animal Research. 
Endothelial cells infection:
The lentiviruses NLGN2 shRNA, Collybistin shRNA (XM_377014-TRCN0000047617) and CTRL shRNA (RNAi Consortium library SIGMA) were produced as described [6] .
One day before the infection, ECs were seeded at concentration of 3,5x10 4 cells/ml in a 100 mm tissue culture dish. Then the cells were transduced for 36h with the lentiviral particles in the presence of 8 μg/ml Polybrene (Sigma-Aldrich). Before starting every experiment, the efficiency of cell infection was determined by analyzing gene downregulation by qRT-PCR.
In vitro cord formation assay: For in vitro cord formation BME was added to each well at a concentration of 8 mg/ml and incubated at 37°C for 30 minutes to allow gel formation. Scramble control and NLGN2 silenced ECs Retinal whole mount staining and confocal imaging analysis: Mouse retinas dissection and whole mount immunostaining were performed as previously described [7] with modifications. Eyes were harvested at P5 and fixed in 4% paraformaldehyde (PFA) for 1 hour in ice. Retinas were dissected and washed briefly with DPBS (Sigma) three times and incubated overnight at 4°C in DPBS containing 0.5% Triton X-100 and 0.2% BSA. The retinas were rinsed briefly with DPBS containing 1% Triton X-100 and then incubated overnight at 4 °C in DPBS 1% Triton X-100 with specific antibodies against: Isolectin B4 (40 μg/ml); von Willebrand Factor (vWF Confocal images were acquired using a confocal laser-scanning microscope (TCS SP2 with DM IRE2; Leica). Images were acquired using a confocal laser-scanning microscope (TCS SP2 with DM IRE2; Leica) and quantified with Image J as follow: the immunoreactivity of each antigen was calculated as the surface area stained by the corresponding antibody normalized on the total surface vascular area visualized by Isolectin B4.
For each quantification at least 6 tumors/genotype were analyzed.
Statistical Analysis: Upon verification of normal distribution, the statistical significance of raw data between the groups in each experiment was evaluated using the unpaired Student's t-test or ANOVA followed by the Bonferroni post-test. Results are expressed as means ± standard error of the mean (SEM) when derived from averaged experiments, or means ± standard deviation (SD) when derived from several data points of one experiment. n represents the number of individual experiments. The asterisks and circles */°, **/°° and ***/°°° in figure panels refer to statistical probabilities (P) of <0.05, <0.01 and <0.001, respectively.
Results
NLGN2 and its intracellular partner collybistin modulate Ang2 and vWF release
Our initial analysis showed that Ang2 release in the medium of ECs was sharply reduced by NLGN2 silencing both in basal conditions and upon VEGF stimulation, but not upon stimulation with the protein kinase C (PKC) activating phorbol ester PMA (phorbol 12-myristate 13-acetate [4] ) ( Figure 1A ).
We next focused on the relations between VEGF, NLGN2, and Ang2. NLGN2 downregulation strongly impaired the time-dependent VEGF-induced discharge of WPB from cells, as measured by the amount of Ang2 or vWF within the cells ( Figure 1B) . Similarly, in vivo, in the postnatal mouse retinal vasculature, the absence of NLGN2 induced an increase in intracellular vWF ( Figure 1C ). In contrast, NLGN2 overexpression in ECs almost doubled the amount of Ang2 released in the medium (Figure 2A ) while strongly reducing both Ang2 and vWF cell content ( Figure 2B ). This effect was totally independent of VEGF addition (data not shown).
Importantly, neither NLGN2 silencing nor overexpression altered the amount of Ang2 mRNA ( Figure S1A, B) .
We next reasoned on the NLGN2 molecular partners that could potentially be involved in these activities. Two candidates stood out for their properties. One was the family of exchange proteins activated by cAMP (Epac), which are activators of the small G protein RAP [8] . EPAC proteins have been implicated in various exocytotic processes including WPB release [9] , and an EPAC isoform (EPAC2/RAPGef4) is known to interact with NLGN2 in neurons [10] . Most of the EPAC-including pathways also involve cAMP signaling through protein kinase A (PKA) [8] and, interestingly, VEGF induced WBP exocytosis is dependent at least in part on cAMP/PKA pathway [11] . Unexpectedly, however, neither NLGN2 overexpression nor silencing was able to modulate RAP1 or PKA activity upon VEGF stimulation ( Figure S2A , B, and data not shown). On the other hand, by the independence of PMA-induced release of Ang2 from NLGN2 ( Figure 1A) , PKC activity was unaffected by NLGN2 expression ( Figure S2C ).
The second candidate was the neuronal GEF collybistin (CB), a CDC42 activator [12] . In neurons, NLGN2 binds CB and shifts its equilibrium towards an active conformation to regulate the organization of inhibitory postsynaptic densities [13] . Our data showed that CB is expressed by ECs ( Figure S3A ) and colocalizes with NLGN2 ( Figure S3B ), while CB silencing inhibits VEGF activity by causing Ang2 and vWF retention in cells, comparably to NLGN2 downregulation ( Figure S3C, D) . Moreover, NLGN2 silenced ECs showed a total loss of CB organization ( Figure S3E ). On the other hand, NLGN2 activity through overexpression, which promotes a strong depletion of Ang2 and vWF from cells even in the absence of VEGF (Figure 2A ) was independent of CB expression ( Figure S3H ).
NLGN2 modulates in vitro and in vivo vascular morphogenesis
Next, we set out to evaluate if NLGN2 affected the angiogenic activities of VEGF on ECs and how this was dependent on Ang2. In vitro, NLGN2 downregulation changed the VEGF-induced cord formation of ECs on Matrigel by increasing the total tube length of the vasculature, while the simultaneous addition of exogenous Ang2 restored the normal phenotype ( Figure 3A ). To demonstrate a role of NLGN2 in physiological angiogenesis we used NLGN2 null mice. In these mice, the total vascular area in the neonatal retina and the density of the meshes were increased, while the typical hierarchical organization of the mature vascular trees was lost ( Figure 3B ). Interestingly, consistent with an agonist role of Ang2 on Tie2 in this context, Tie2 phosphorylation was reduced in retinas of NLGN2 null mice ( Figure 3C ). Parallel to the abnormal vessel growth there was a reduced pericyte coverage of retinal vessels ( Figure 4A 
Discussion
This study is a follow-up to other three reports from our laboratory that demonstrate a role for the synaptic proteins Neuroligins in vascular biology [1, 6, 14] . In particular, we reveal that the major "inhibitory isoform" of the NLGN family helps regulate the secretion of Ang2 and vWF from ECs.
Based on our data we assume that NLGN2 modulates VEGF-induced vWF/Ang2 release without a distinct involvement of the main molecular partners that we considered: the EPAC/RAP, PKA, or PKC pathways [9, 11, 15] . Besides the complexity of the WPB machinery itself [16] two factors may have impaired our understanding of the VEGF-NLGN2 downstream axis. First, NLGN2 itself modulates exocytosis in pancreatic beta cells through a complex transcellular mechanism that is also context and model dependent [2, 17] . Second, VEGF plays a dual role in regulating endothelial exocytosis, triggering pathways that both promote and inhibit this process [18] .
Nevertheless, we find that NLGN2 cooperates with yet a novel endothelial mediator, the neuronal GEF CB.
Hence, one possibility is that NLGN2 affects exocytosis by modulating the exocyst complex and vesicle docking through a CB-CDC42 axis [19] . Indeed, immunodetection of active CDC42 in ECs shows that NLGN2 silencing reduces the activity of CDC42 to the same extent as CB downregulation does, at least in basal conditions ( Figure   S4 ).
We show that in vitro and in vivo NLGN2 deletion influences vascular morphogenesis. Our data support the idea that Ang2, at least at the concentrations controlled by NLGN2 in vivo, is a Tie2 agonist. While the original view in the vascular field was that Ang2 produced by VEGF-activated endothelium inhibits Tie2 activity, destabilizes blood vessels and induces pericyte loss [20] , this antagonist hypothesis has been challenged and the activity of Ang2 has been proposed to be context-dependent. In particular, Ang2 has been reported to function as a Tie2 activator in human tumor xenografts [21] . Accordingly, we show that a lack of NLGN2 in the host induces pericyte loss during the vascular development of the retina and it exacerbates the same phenotype in the already abnormal tumor vasculature. Hence, we hypothesize that NLGN2 silencing in EC causes a loss of an agonist activity of Ang2.
In conclusion, this study along with our previous one [1] reveals that NLGN2, unlike NLGN1, modulates vessel functions not by affecting the extracellular matrix adhesive properties of ECs, but by regulating the release of WPBs, with their large cytokine load and activities ranging from hemostasis to inflammation, to tumor metastasis [3] . 
